Regulatory
FDA Approves Bristol Myers’ Zenbexus, the First of a New Class of Myeloma Drugs
Iberdomide is the first approved CELMoD — a next-generation protein degrader — cleared in a three-drug combination for multiple myeloma as early as first relapse.